Antiplatelet Management for Elderly MI Patient with Recent UGIB

Introduction to Antiplatelet Therapy

The European Society of Cardiology recommends aspirin monotherapy (75-100 mg daily) with mandatory proton pump inhibitor (PPI) co-therapy for elderly patients with recent UGIB and no coronary stenting, avoiding dual antiplatelet therapy (DAPT) due to the high bleeding risk 1, 2

The European Heart Journal states that for MI patients managed medically without PCI, DAPT is only a Class IIa recommendation, and the bleeding risk substantially outweighs any potential ischemic benefit from DAPT in patients with recent UGIB 1
The American College of Cardiology indicates that aspirin 75-100 mg daily is Class I recommended for all post-MI patients regardless of revascularization strategy, with a 23% reduction in 35-day mortality demonstrated in ISIS-2 1, 3

The European Society of Cardiology recommends PPI co-prescription as Class I for patients at high risk of gastrointestinal bleeding, which includes elderly patients with recent GI bleeding and antiplatelet therapy requirement 1
The American College of Cardiology suggests that PPIs should be continued indefinitely while on any antiplatelet therapy to reduce recurrent bleeding risk 2

The European Heart Journal recommends that before considering any escalation to DAPT, complete upper and lower GI endoscopy must be performed to identify and treat the bleeding source, and hemoglobin should be stabilized and remain above 12 g/dL 4, 2
The American College of Cardiology advises testing and treating for H. pylori if present, as eradication significantly reduces ulcer recurrence and rebleeding rates, and allowing adequate time (typically 4-6 weeks) for GI lesions to heal before considering any second antiplatelet agent 2, 4

The American College of Cardiology recommends never discontinuing aspirin completely in a post-MI patient unless there is active, life-threatening bleeding, as complete cessation of antiplatelet therapy significantly increases mortality risk even in medically managed MI patients 3, 2, 1
The European Society of Cardiology advises avoiding the use of ticagrelor or prasugrel in elderly patients with recent GI bleeding, as this inappropriately escalates bleeding risk without proven benefit in non-PCI patients 2